Document is current
Any future updates will be listed below
-
Authors
Kondoh, Yasuhiro https://orcid.org/0000-0001-7456-5459
Ito, Tomohiro https://orcid.org/0000-0002-6456-2825
Kimura, Hana https://orcid.org/0009-0006-4704-5435
Bao, Haikun
Kuwana, Masataka https://orcid.org/0000-0001-8352-6136
-
Funding
Funding for this research was provided by:
Nippon Boehringer Ingelheim Co. Ltd.
- License Information
-
More Information
Article History
Received: 18 December 2024
Accepted: 8 May 2025
First Online: 22 May 2025
Declarations
:
: The study was designed, conducted, and reported using best practice guidelines, with Institutional Review Board (IRB) approval from the Takahashi Clinic Ethics Committee on December 5, 2023 (IRB approval number: LNW00207). Hence, all objectives and methods were pre-specified and executed according to the study protocol. This study used anonymised processed information from the Medical Data Vision database and therefore informed consent to participate was deemed unnecessary according to Ethical Guidelines for Medical and Biological Research Involving Human Subjects (2023 Revision) by the Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare, and Ministry of Economy, Trade and Industry, in Japan. In addition, as this study used anonymised processed information from the Medical Data Vision database, the Declaration of Helsinki is not applicable.
: Not applicable.
: Yasuhiro Kondoh has received consulting fees from Asahi Kasei Pharma Corp, Boehringer Ingelheim, Chugai Pharmaceutical Co., Ltd., Healios K.K., Janssen Pharmaceutical KK, Shionogi Co, Ltd., and Taiho Pharmaceutical Co., Ltd., and serves on speaker bureaus for Asahi Kasei Pharma Corp, Boehringer Ingelheim, Eisai Co, Ltd, Bristol Myers Squibb, Janssen Pharmaceutical K.K., KYORIN Pharmaceutical Co, Ltd, Mitsubishi Tanabe Pharma, NIPPON SHINYAKU CO., LTD, Novartis Pharma KK, Shionogi Co, Ltd., and Teijin Pharma Ltd. Tomohiro Ito, Hana Kimura, and Haikun Bao are employees of Boehringer Ingelheim. Masataka Kuwana has received consulting fees, speaking fees, and research grants from AbbVie, argenx, Asahi Kasei, AstraZeneca, Astellas, Boehringer Ingelheim, Chugai, Corbus, Eisai, GlaxoSmithKline, Horizon, Janssen, Kissei, MBL, Mitsubishi Tanabe, Mochida, Nippon Shinyaku, Ono Pharmaceuticals, Pfizer, and Taisho. Tomohiro Ito, Hana Kimura, and Haikun Bao are employees of Boehringer Ingelheim.
